Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
10.64
-0.26 (-2.39%)
At close: Nov 14, 2025, 4:00 PM EST
10.66
+0.02 (0.19%)
After-hours: Nov 14, 2025, 4:10 PM EST
Contineum Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
41
Market Cap
311.09M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 50.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCTNM News
- 15 days ago - Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones - Business Wire
- 2 months ago - Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 - Business Wire
- 2 months ago - Contineum Therapeutics to Present at September Investor Conferences - Business Wire
- 3 months ago - Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones - Business Wire
- 5 months ago - Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 - Business Wire
- 6 months ago - Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference - Business Wire
- 6 months ago - Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones - Business Wire
- 7 months ago - Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development - Business Wire